Inclusion Criteria:

- informed of the study and have provided written informed consent

- At least 18 years of age

- Histologically confirmed diagnosis of locally advanced, or metastatic squamous cell
carcinoma or adenocarcinoma histological subtypes of non-small-cell lung cancer
(stage IIIB or IV)

- For patients with squamous cell histology: previously treated with first-line
chemotherapy and has had disease progression during or after first-line therapy.

- For patients with adenocarcinoma histology: previously treated with one or two lines
of chemotherapy.

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Life expectancy ≥ 3 months

- Measurable disease by RECIST 1.1 criteria

- Hematology values: blood leukocyte count ≥ 3.0 x 109/L, blood absolute neutrophil
count ≥ 1.5 x 109/L, blood platelet count ≥ 100 x109/L, hemoglobin ≥ 100 g/L
(transfusions are allowed)

- Clinical chemistry values: plasma total bilirubin level ≤ upper limit of the "normal"
range (ULN; i.e. reference), plasma AST or ALT ≤ 1.5 x ULN (≤ 5 times if liver
metastases have been documented) and plasma creatinine ≤ 2.0 x ULN

- 12-lead ECG with normal tracings

Exclusion Criteria:

- Mixed histology of squamous and non-squamous NSCLC

- Ongoing infection or other major recent or ongoing disease that, according to the
Investigator, poses an unacceptable risk to the patient

- Known primary or secondary central nervous system malignancy.

- Active or previously treated carcinomatous meningitis

- Truly non-measurable disease by RECIST 1.1 criteria, such as patients with one or
more of the following without any RECIST measurable disease:

- Bone lesions

- Ascites

- Pleural or pericardial effusion

- Lymphangitis cutis or pulmonis

- Cystic lesions

- Grade 3 or higher constipation within the past 28 days or grade 2 constipation within
the past 14 days before randomization.

- Active hepatitis B, active hepatitis C, or known HIV infection

- Coexisting uncontrolled medical condition, including active cardiac disease (such as
unstable angina, myocardial infarction within 6 months, or New York Heart Association
Class III/IV congestive heart failure), and significant dementia

- Hepatic impairment as indicated by abnormalities of transaminases (AST and/or ALT >
1.5 × ULN or AST and/or ALT > 5 times ULN if liver metastases have been documented)
and/or increased alkaline phosphatase (> 2.5 × ULN) considered as a result of hepatic
impairment (and not from bone disease)

- History of cancer that has required treatment or been active within the past 5 years,
other than NSCLC, basal cell carcinoma, or cervical carcinoma in situ

- Major surgical procedure within 4 weeks prior to randomization

- More than one prior anti-tumor systemic therapy for advanced squamous cell NSCLC, and
more than two prior lines of chemotherapy for advanced adenocarcinoma NSCLC

- Previous use of docetaxel in any line of therapy

- Women of child bearing potential (WOCBP) who do not consent to using acceptable
methods of contraception

- Women who are breast-feeding or have a positive pregnancy test at screening

- Current participation in any other investigational clinical trial or any
administration of an investigational agent within 4 weeks of study drug
administration

- ECOG performance status > 2

- Life expectancy < 3 months

- Known or suspected hypersensitivity to AXL1717 or docetaxel or to drugs formulated
with polysorbate 80

- Lack of suitability for participation in the trial, for any reason, as judged by the
Investigator